Extrapleural Pneumonectomy (EPP): Comprehensive Surgery Guide for Mesothelioma

What is Extrapleural Pneumonectomy?

Extrapleural pneumonectomy (EPP) is an extensive surgical procedure designed to remove all visible mesothelioma tumor, including the entire affected lung, pleura (lining), diaphragm, and pericardium (heart sac lining). It's one of the most aggressive surgical approaches available.

Components of EPP Surgery

Pneumonectomy: Removal of the entire lung on the affected side. This is the main component that distinguishes EPP from other procedures and results in permanent loss of 50% of normal lung capacity.

Pleural removal: Complete resection of both visceral and parietal pleura, which are the linings surrounding the lung and chest wall.

Diaphragm resection: The diaphragm on the affected side is often removed and reconstructed with synthetic mesh material to maintain chest wall integrity and breathing mechanics.

Pericardial resection: The pericardium (sac around the heart) is sometimes removed and reconstructed with synthetic material if invaded by tumor.

Why This Aggressive Approach?

EPP allows the most complete removal of visible mesothelioma tumor. For patients with advanced disease (Stage III) where tumor has infiltrated deeper structures, EPP provides the best chance for R0 resection (complete tumor removal), which significantly impacts survival outcomes.

History and Development of EPP for Mesothelioma

Extrapleural pneumonectomy has evolved significantly since its inception.

Early Development

EPP was originally developed in the mid-20th century as treatment for tuberculosis before modern antibiotics became available. It was adapted for mesothelioma treatment in the 1990s as oncologists recognized the need for aggressive surgical approaches to this aggressive cancer.

Peak Use Period (1990s-2000s)

In the 1990s and early 2000s, EPP became the standard surgical approach for mesothelioma at major medical centers. Many thoracic surgeons were trained in the procedure, and it was considered the gold standard for potentially curable treatment.

Current Status and Evolution

Over the past 15 years, there's been increasing debate about EPP versus pleurectomy/decortication (P/D). Some data suggests P/D combined with chemotherapy produces comparable survival to EPP with better quality of life. This has led to a shift in some centers toward lung-preserving approaches, though EPP remains standard at high-volume mesothelioma centers for appropriately selected patients.

Who is a Good Candidate for Extrapleural Pneumonectomy?

Careful patient selection is critical for EPP success. Not all mesothelioma patients can tolerate or benefit from this extensive procedure.

Ideal EPP Candidates

• Stage III mesothelioma: Disease with extensive pleural involvement, diaphragmatic invasion, or pericardial involvement
• Age: Typically under 75 years (though age alone is not absolute contraindication)
• Performance status: Able to tolerate 3-6 hour surgery and extensive recovery
• Contralateral lung function: Remaining lung must have FEV1 ≥40% and adequate gas exchange
• Cardiac function: Ability to tolerate single-lung operation; ejection fraction typically ≥45%
• No major comorbidities: Diabetes, hypertension, and other conditions well-controlled
• Adequate nutritional status: Can tolerate major surgery and extended recovery
• Resectability: Tumor deemed resectable by experienced mesothelioma surgeon

Contraindications to EPP

• Poor performance status or significant comorbidities
• Inadequate function of remaining lung (FEV1 <40%)
• Severe cardiac disease or reduced ejection fraction
• Uncontrolled diabetes or other medical conditions
• Advanced age with multiple medical problems
• Distant metastases (stage IV disease)
• Medical comorbidities making anesthesia very high-risk

The Pre-Operative Assessment

Patients considered for EPP undergo comprehensive testing including chest CT, PET scan, pulmonary function tests, cardiac assessment (EKG, echocardiogram), and functional evaluation to ensure fitness for surgery. This assessment takes 2-4 weeks and determines final candidacy.

The EPP Procedure: Detailed Step-by-Step

Understanding the actual surgical procedure helps patients understand the scope of EPP and what to expect.

Pre-Operative Setup

• General anesthesia with double-lumen endotracheal tube (allowing selective lung ventilation)
• Placement of arterial and central venous lines for continuous monitoring
• Foley catheter for urine monitoring
• Positioning for optimal surgical access (typically lateral decubitus)
• Surgical team includes thoracic surgeon, cardiac surgeon (standby), anesthesiologist, perfusionist

Surgical Steps

1. Incision: A long posterolateral thoracotomy incision is made, typically from below the scapula extending across to near the sternum. This large incision provides complete access to the entire hemithorax.

2. Extrapleural dissection: The surgeon separates the parietal pleura from the inner chest wall (ribs and intercostal muscles). This extrapleural plane is maintained throughout the dissection to avoid entering the pleural space where tumor might be.

3. Hilar dissection: The lung hilum (where vessels and bronchus enter) is identified and carefully dissected. Major blood vessels (pulmonary artery and vein) are isolated and prepared for division.

4. Lung removal: The main pulmonary artery is divided and ligated, followed by division of the main pulmonary vein. The main bronchus is stapled and divided, removing the entire lung.

5. Diaphragm resection: If tumor has invaded the diaphragm, it is resected along with a margin of normal diaphragm muscle. A synthetic patch (Marlex or Gore-Tex) is sutured in place to restore the diaphragm and allow breathing mechanics.

6. Pericardial resection: If pericardium is involved by tumor, it is opened and the invaded portion is resected. If the defect is large, a patch is placed to protect the heart.

7. Chest wall reconstruction: After pleural and diaphragmatic removal, the chest wall configuration is altered. Reconstruction with synthetic material helps maintain chest wall integrity and prevents paradoxical breathing.

8. Final hemostasis and inspection: All bleeding sites are controlled with electrocautery, ligatures, and hemostatic agents. The entire surgical field is inspected for bleeding, adequacy of resection, and complications.

9. Chest tube placement: One to three chest tubes are placed to drain air and fluid from the chest cavity.

10. Closure: The chest wall is closed in multiple layers using absorbable sutures deep to the muscle and skin sutures or staples superficially.

Operative Duration and Complexity

EPP typically takes 3-6 hours depending on disease extent, surgeon experience, and intraoperative complications. This makes it one of the longest and most complex thoracic procedures.

Recovery Timeline After Extrapleural Pneumonectomy

Recovery from EPP is more extensive and prolonged than from pleurectomy decortication due to the magnitude of the surgery.

Immediate Post-Operative Period (Days 1-7)

• ICU admission for 1-2 weeks with continuous cardiac and hemodynamic monitoring
• Mechanical ventilation initially, then gradual weaning
• Multiple monitoring lines and catheters
• Aggressive pain management with epidural and IV medications
• Multiple chest tubes draining large volumes initially
• Focus on breathing exercises and preventing complications
• Early mobilization as tolerated

Hospital Stay (Days 8-21)

• Transition to regular hospital floor after ICU stabilization
• Gradual removal of chest tubes as drainage decreases
• Progressive physical therapy and breathing exercises
• Transition to oral pain medications
• Education about living with single-lung function
• Discharge typically after 3-4 weeks (longer than P/D)

Home Recovery (Weeks 1-12)

Weeks 1-4: Very limited activity. Focus on rest, pain management, breathing exercises. Avoid activity that increases exertion. Frequent outpatient appointments and chest X-rays to monitor air spaces and fluid accumulation.

Weeks 5-8: Gradual activity increase under medical guidance. Can attempt short walks. Some patients begin outpatient cardiac rehabilitation. Still significant activity restrictions.

Weeks 9-12: Most patients achieve basic functioning and can manage activities of daily living. Still may have significant fatigue and breathing limitations.

Long-Term Adaptation

Patients spend 6-12 months adapting to single-lung function. The remaining lung gradually enlarges and develops improved function, but never fully replaces the removed lung. Many patients report that breathing, exercise capacity, and quality of life stabilize after 6-12 months, though activity restrictions remain permanent.

Survival Statistics & Outcomes

Understanding realistic survival expectations helps patients understand treatment goals.

Median Overall Survival Rates

• EPP alone: 9-12 months
• EPP + chemotherapy: 14-24 months depending on regimen and response
• EPP + chemotherapy + radiation: Up to 24-30 months in selected cases

Factors Affecting EPP Outcomes

• Stage at diagnosis: Stage III patients have better outcomes than Stage IV
• Histological type: Epithelioid histology better than sarcomatoid
• R0 resection: Complete tumor removal significantly improves survival
• Age and fitness: Younger, healthier patients have better outcomes
• Chemotherapy response: Good response to treatment improves long-term survival
• Blood markers: Pre-operative biomarkers (mesothelin, fibulin-3) may predict outcomes

Comparison to P/D Outcomes

Recent studies suggest that P/D combined with chemotherapy may produce comparable or slightly superior median survival compared to EPP with chemotherapy (18-30 months for P/D vs 14-24 months for EPP), though EPP allows more complete tumor removal in advanced cases. The debate about optimal procedure continues among thoracic surgeons.

Risks & Potential Complications of EPP

Because EPP is so extensive, it carries significant risks that must be understood and accepted by candidates.

Early Complications (During Hospital Stay)

• Air leaks: Continued air leaking from remaining lung, requiring prolonged chest tube drainage
• Bleeding: Excessive bleeding requiring transfusion or return to OR
• Infection: Pneumonia, empyema (infected fluid), or surgical site infection
• Cardiac complications: Arrhythmias, low cardiac output, heart failure
• Pulmonary embolism: Blood clots in the remaining lung (potentially fatal)
• Bronchopleural fistula: Air leak at the bronchial stump (serious complication)
• Hepatic infarction: Liver damage from positioning and manipulation
• Respiratory failure: Inadequate oxygenation requiring prolonged ventilation

Late Complications (Weeks to Months)

• Chronic pain: Persistent chest wall or neuropathic pain
• Pulmonary compromise: Significant permanent reduction in exercise capacity and breathing
• Infection: Late infection of the empty hemithorax space (empyema)
• Paradoxical breathing: Abnormal chest wall movement affecting respiration
• Cardiac strain: Right heart strain from loss of lung and increased workload
• Quality of life limitations: Permanent inability to exercise, climb stairs, or perform strenuous activities

Mortality Risk

In-hospital mortality for EPP ranges from 2-4% at experienced centers, but can be higher (5-8%) at less experienced centers. This represents a meaningful risk that must be discussed and accepted by patients.

The EPP vs P/D Debate: Current Surgical Thinking

The mesothelioma surgical community has evolved significantly regarding the optimal procedure.

Traditional Thinking (1990s-2000s)

EPP was considered the gold standard for potentially curable mesothelioma treatment, with the philosophy that "more extensive surgery equals better outcomes." Many surgeons trained exclusively in EPP.

Contemporary Evidence (2010s-2020s)

Several important studies challenged this assumption. The MARS trial (a randomized trial in the UK) suggested EPP provided no survival benefit over chemotherapy alone and was associated with high morbidity. Modern studies increasingly show that P/D combined with rigorous chemotherapy produces comparable or superior survival to EPP while preserving lung function and quality of life.

Current Consensus

Most high-volume mesothelioma centers now use a lung-preserving approach (P/D) as the preferred first-line surgical option for early-stage disease. EPP is reserved for Stage III patients with extensive tumor burden unsuitable for P/D, or patients who prefer the most aggressive approach despite quality-of-life considerations. The choice should be individualized based on stage, tumor extent, and patient preferences.

Shared Decision Making

Modern mesothelioma care emphasizes shared decision-making where surgeons discuss both options thoroughly, explaining potential benefits and risks of each approach. Patient preference and values now play a larger role than they did in the past.

Medical References

1. Treasure T, et al. (2011). Mesothelioma trials and operational research in thoracic surgery. Lancet Oncol, 12(10):901-909. PMID: 20933467
2. Flores RM, et al. (2012). Extrapleural pneumonectomy for pleural mesothelioma. Thorac Surg Clin, 22(3):409-419. PMID: 22813568
3. Sugarbaker DJ, et al. (2013). Adult Chest Surgery (3rd ed.). McGraw Hill Professional.
4. Baas P, et al. (2015). Malignant pleural mesothelioma. Nat Rev Dis Primers, 3:1-20. PMID: 27277755
5. Pass HI, et al. (2012). Mesothelioma research: a review of animal models and mechanistic studies. Ann Thorac Surg, 95(5):1787-95. PMID: 22583533